Education, Science, Technology, Innovation and Life
Open Access
Sign In
  1. Home
  2. Journals
  3. MEDS Chinese Medicine
  4. Vol 5, Issue 3, 2023

Active Components and Mechanism of Dihuang Yinzi in Treatment of Vascular Dementia Based on Network Pharmacology and Molecular Docking Technology

Download as PDF

DOI: 10.23977/medcm.2023.050301 | Downloads: 10 | Views: 479

Author(s)

Tang Ju 1, Miao Feng 2, Ma Yilun 1, Ren Hui 1, Wei Peifeng 2

Affiliation(s)

1 Shaanxi University of Traditional Chinese Medicine, Xianyang, 712046, China
2 The Second Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang, 712000, China

Corresponding Author

Miao Feng

ABSTRACT

The objective this study aims to look into the active ingredients and mechanism of Dihuang Yinzi in the treatment of vascular dementia (VaD) using network pharmacology and molecular docking technology. Methods Based on network pharmacology, screening of the chemical composition and its role of Dihuang Yinzi targets, disease targets, intersection targets, and other related information, and then based on bioinformatics technology, the key pathways related annotation, the active components of Dihuang Yinzi intervention vascular dementia and the underlying mechanisms, and then will get key components and key targets for molecular docking. Results According to network pharmacology, the active ingredients of Dihuang Yinzi in the treatment of VaD were Stigmasterol, beta-sitosterol, Erianin, and others. Dihuang Yinzi's signaling pathways in the treatment of VaD primarily include lipid and atherosclerosis, the PI3K-Akt signaling pathway, the TNF signaling pathway, apoptosis, and so on. Stable structures can be formed by docking key targets with key component molecules. Conclusion Dihuang Yinzi works by using several components, multiple targets, and multiple pathways to cure and prevent VaD.

KEYWORDS

Dihuang Yinzi, Vascular Dementia, Network Pharmacology, Molecular Docking Technology

CITE THIS PAPER

Tang Ju, Miao Feng, Ma Yilun, Ren Hui, Wei Peifeng, Active Components and Mechanism of Dihuang Yinzi in Treatment of Vascular Dementia Based on Network Pharmacology and Molecular Docking Technology. MEDS Chinese Medicine (2023) Vol. 5: 1-7. DOI: http://dx.doi.org/10.23977/medcm.2023.050301.

REFERENCES

[1] Francesco, Iemolo, Giovanni, et al. Pathophysiology of vascular dementia. Immunity & Ageing, 2009, 6(1):13-13.
[2] Huang W. Research progress in the pathogenesis of vascular dementia. Chin Med Guide, 2012, 10(5):3. (in Chinese)
[3]  Gao Fengchao, Chen Xiang, Tian Xinying. Research progress of risk factors and pathogenesis of vascular dementia. Medical Review, 2014, 20(06):1068-1071.
[4] Wang W, Yu W T, Nie J T, et al. Study on the characteristics of TCM syndromes of vascular dementia patients. Chinese Journal of Basic TCM Medicine, 2017, 23(4):5.
[5] Yang C H, Wang Y Y. The pathogenesis and treatment of vascular dementia in Chinese medicine. Chinese Medicine Research, 2005, 18(5):2.
[6] Jung E Y, Lee M S, Ahn C J, et al. The Neuroprotective Effect of Gugijihwang-Tang on Trimethyltin-Induced Memory Dysfunction in the Rat. Evidence-Based Complementray and Alternative Medicine,2013, (2013-6-4), 2013, 2013:542081.
[7] Jinlong Ru; Peng Li; Jinan Wang; Wei Zhou; Bohui Li; Chao Huang; Pidong Li; Zihu Guo; Weiyang Tao; Yinfeng Yang; Xue Xu; Yan Li; Yonghua Wang; Ling Yang. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. J Cheminformatics. 2014 Apr 16; 6(1):13.
[8] M Álvarezsaúco, JM Moltójordà, Moreraguitart J, et al. An update on the diagnosis of vascular dementia. Revista De Neurologia, 2005, 41(8):484.
[9] Wang XX, Zhang B, Xia R, Jia QY. Inflammation, apoptosis and autophagy as critical players in vascular dementia. Eur Rev Med Pharmacol Sci. 2020 Sep; 24(18):9601-9614.
[10] Wang Feixue, Huang Xiaobo, Pei Hui, et al. Inheritance and development of TCM pathogenesis theory of vascular dementia. World of Traditional Chinese Medicine, 202, 17(2):5.
[11] Zhou Zhiyuan, Lu Qun, Liu Yang, et al. Research and development progress of stigmasterol. Chinese Journal of Contemporary Medicine, 2015, 22(24):3. (in Chinese)
[12] Chen Yuankun, Zeng Ao, LUO Zhen-hui, et al. Advances in pharmacological effects of β-sitosterol. Journal of Guangdong Pharmaceutical University, 2021.
[13] Song JX, Shaw PC, Wong NS, Sze CW, Yao XS, Tang CW, Tong Y, Zhang YB. Chrysotoxine, a novel bibenzyl compound selectively antagonizes MPP⁺, but not rotenone, neurotoxicity in dopaminergic SH-SY5Y cells. Neurosci Lett. 2012 Jul 11; 521(1):76-81.
[14] Zheng G, Wang L, Li X, et al. Rapamycin alleviates cognitive impairment in murine vascular dementia: The enhancement of mitophagy by PI3K/AKT/mTOR axis. Tissue and Cell, 2020, 69:101481. 
[15] Wang Mingwei, Xie Ximei, Zhang Xulong, et al. Study on the mechanism of acupuncture in central nervous system diseases based on PI3K/Akt signaling pathway. Journal of Acupuncture and Moxibustion, 201, 37(9):4.
[16] Wang, Kai et al. “Network pharmacology-based prediction of the active compounds and mechanism of Buyang Huanwu Decoction for ischemic stroke.” Experimental and therapeutic medicine vol. 22, 4 (2021): 1050. 
[17] Liu Xian, Wu Tian, Liu Meng, et al. Effect of Danggui Shaoyao Powder on vascular dementia through PI3K/AKT signaling pathway. New Chinese Medicine and Clinical Pharmacology, 2019, 30(3):7.
[18] Prasad K. Pathophysiology and Medical Treatment of Carotid Artery Stenosis. Int J Angiol. 2015; 24(3):158-172.

Subscription
E-Mail Alert
Most popular papers
Call for Special Issue
Publication Ethics & OA Statement
Plagiarism Policy
Contact Us
Downloads: 4240
Visits: 168168

Sponsors, Associates, and Links

All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.